论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liu Z, Zhang Y, Chen Y, Lin Y, Lin Z, Wang H
Received 31 July 2018
Accepted for publication 4 November 2018
Published 29 November 2018 Volume 2018:10 Pages 6517—6523
DOI https://doi.org/10.2147/CMAR.S182105
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Professor Nakshatri
Background: Signal
transducer and activator of transcription (STAT) 1 is an important
transcription factor and has been reported to be a tumor suppressor in many
types of cancer. However, another STAT family member, STAT3, is considered to
be an oncogene. The cross-talk between STAT1 and STAT3 in cancer has not been
fully demonstrated.
Materials and methods: Esophageal
squamous cell carcinoma (ESCC) was used as a model to examine STAT1-STAT3
cross-regulation in cancer. We detected STAT1-STAT3 binding by
co-immunoprecipitation (co-IP) and measured the transcription activity by using
a luciferase reporter gene. DNA binding was detected by a DNA probe. Expression
of STAT1 and STAT3 in ESCC was detected by immunohistochemistry.
Results: We found that
STAT1 attenuated STAT3 activity upon oncostatin M treatment by decreasing STAT3
transcription activity and DNA binding ability of STAT3. Furthermore STAT3
downregulation increased the phosphorylation and transcriptional activation of
STAT1. Finally, STAT1 expression and STAT3 expression were negatively
correlated in ESCC cases.
Conclusion: Altogether,
this paper demonstrated STAT1 and STAT3 cross-regulation in ESCC and proposed
that STAT3 downregulation and/or STAT1 accumulation may be a therapeutic
approach to treat ESCC.
Keywords: STAT1,
STAT3, esophageal squamous cell carcinoma, transcription activity
